Optiscan submits a **510(k) clearance application** to the US FDA for **InVue**, its real-time digital surgical microscope. The device integrates imaging technology for point-of-care surgical use. Dr. Camile Farah, CEO of Optiscan, discusses the milestone in a recent interview.
Optiscan Imaging demonstrates the InForm device in a digital pathology study covering over 80 cases without traditional glass slides. The slide-free approach aims to streamline clinical validation and expand adoption in pathology workflows.
Optiscan Imaging (ASX:OIL) is progressing its FDA approval strategy for its InSpecta product line, which includes a newly launched commercial pathway. The company aims to expand market access for its medical imaging solutions, targeting regulatory and commercial milestones in the U.S. healthcare sector.
OptiScan Imaging completes **Stage 2** of its **head and neck cancer live-imaging study** ahead of schedule, expediting clinical validation. The progress supports faster potential **FDA submissions** for its imaging technology, which may improve real-time tumor assessment during treatments.
